Establishing the dose response curve for metabolic control with troglitazone, an insulin action enhancer, in type 2 diabetes patients

Annals of Medicine

Volumn 30, Issue 2, 1998, Pages 206-212

  Young, Malcolm A ^a   Eckland, David J A ^a   Eastmond, Richard ^a   Lettis, Sally ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Cardiovascular risk factors; Glycaemic control; Non insulin dependent diabetes mellitus; Troglitazone

Indexed keywords

FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL; TROGLITAZONE;

ADULT; AGED; ARTICLE; BODY WEIGHT; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIURESIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FATIGUE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALAISE; METABOLIC REGULATION; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; POLYURIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SIDE EFFECT; THIRST; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0031979370     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899808999405     Document Type: Article

References (25)

1. Fujiwara T, Wada M, Fukuda K, et al. Characterisation of CS-045, a new oral antidiabetic agent. II. Effects on glycaemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice. Metabolism 1991; 40 (Suppl 11): 1213-8.
2. Fujiwara T, Okuno A, Yoshioka S, Horikoshi H. Suppression of hepatic gluconeogenesis in long-term troglitazone treated diabetic KK and C57BL/KsJ-db/db mice. Metabolism 1995; 44: 486-90.
3. Sironi AM, Vichi S, Gastaldelli A, et al. Effects of troglitazone on insulin sensitivity and cardiovascular risk factors (CVRF) in NIDDM. Diabetes 1996; 45 (Suppl 2): A680.
4. Lenhard JM, Kliewer SA, Paulik M, et al. Effects of troglitazone and metformin on glucose and lipid metabolism: alterations of two distinct molecular pathways. Biochem Pharmacol 1997; 54: 801-8.
5. Kumar S, Boulton AJM, Beck-Nielsen H, et al. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 1996; 39 (Suppl 6): 701-9.
6. Correa JCN, Hilsted J, Eckland D, Lettis S, Starkie M, Young M, for the Troglitazone Study Group. Investigation of twice or three times daily dose regimen of troglitazone, an insulin action enhancer, in patients with non insulin dependent diabetes mellitus. Eur J Clin Res 1997; 9: 151-65.
7. Leutenegger M, Sacca L, Alderton C, Eckland D, Lettis S, for the Troglitazone Study Group. Double-masked, placebo-controlled, dose-ranging study of troglitazone 10 to 200 mg once daily in NIDDM. Curr Ther Res 1997; 58: 1-14.
8. Foot EA, Patel J, Williams ZV, Eckland DJA. Improved metabolic control by addition of troglitazone to glibenclamide therapy in non-insulin dependent diabetics. Diabetologia 1995; 38 (Suppl 1): A44.
9. Spencer CM, Markham A. Troglitazone. Drugs 1997; 54: 89-101.
10. Altman DG, Bland JM. Measurement in medicine: the analysis of method comparison studies. The Statistician 1983; 32: 307-17.
11. Schwartz G. Estimating the dimension of a model. Ann Stat 1978; 6: 461-4.
12. Akaike A. Posterior probabilities for choosing a regression model. Ann Instit Mathemat Stat 1978; 30: A9-14.
13. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
14. Andersson DKG, Svardsudd K. Long-term glycaemic control relates to mortality in type II diabetes. Diabetes Care 1995; 18: 1534-43.
15. Klein R, Klein BEK, Moss SE. Relation of glycaemic control to diabetic microvascular complications in diabetes mellitus. Ann Intern Med 1996; 124: 90-6.
16. Laakso M. Glycaemic control and the risk for coronary heart disease in patients with non-insulin-dependent diabetes mellitus. The Finnish studies. Ann Intern Med 1996; 124: 127-30.
17. Uusitupa M, Siitonen O, Pyörälä K, et al. The relationship of cardiovascular risk factors to the prevalence of coronary heart disease in newly diagnosed type 2 (non-insulin-dependent) diabetes. Diabetologia 1985; 28: 653-9.
18. Stewart MW, Laker MF, Alberti KGMM. The contribution of lipids to coronary heart disease in diabetes mellitus. J Intern Med 1994; 236 (Suppl 736): 41-6.
19. Fontbonne A. Relationship between diabetic dyslipoproteinaemia and coronary heart disease risk in subjects with non-insulin-dependent diabetes mellitus. Diabetes Metab Rev 1991; 7: 179-89.
20. Randle PJ, Garland PB, Hales CM, et al. The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963; 1: 785-9.
21. Little RR, Wiedmeyer HM, England JD, et al. Interlaboratory standardization of measurements of glycohemoglobins. Clin Chem 1992; 38: 2472-8.
22. Gillery P, Labbe D, Dumont G, Vassault A. Glycohemoglobin assays evaluated in a large-scale quality control survey. Clin Chem 1995; 41: 1644-8.
23. Pickup JC, Crook MA, Tutt P. Blood glucose and glycated haemoglobin measurement in hospital: which method? Diabet Med 1993; 10: 402-11.
24. Cohen MP. Perspective: measurement of circulating glycated proteins to monitor intermediate-term changes in glycaemic control. Eur J Clin Chem Clin Biochem 1992; 30: 851-9.
25. Boden G, Chen X, Desantis RA, Kendrick Z. Effects of insulin on fatty acid reesterification in healthy subjects. Diabetes 1993; 42: 1588-93.